Therapeutic evolution in HR+/HER2- breast cancer: from targeted therapy to endocrine therapy

Therapeutic evolution in HR+/HER2- breast cancer: from targeted therapy to endocrine therapy

Breast cancer, a complex and varied disease, has four distinct subtypes based on estrogen receptor and human epidermal growth factor receptor 2 (HER2) levels, among which a significant subtype known as HR+/HER2-breast cancer that has spurred numerous research. The prevalence of breast cancer and bre...

Full description

Bibliographic Details
Main Authors: Lu-Qi Cao, Haidong Sun, Yuhao Xie, Harsh Patel, Letao Bo, Hanli Lin, Zhe-Sheng Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-01-01
Series:Frontiers in Pharmacology
Subjects:
HR+/HER2-breast cancer
clinical trial
CDK4/6 inhibitor
PI3K inhibitor
SERM
SERD
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2024.1340764/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2024.1340764/full

Similar Items